BOLLÉ-SAFETY
19.4.2021 10:32:04 CEST | Business Wire | Press release
Global eye protection specialist Bollé Safety now provides Trivex. A high-performance, high-technology prescription lens providing maximum security and great optical properties to ensure the best safety in a work environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005013/en/
The best of CR39 and polycarbonate in addition to unique features.
Bollé Safety’s latest lens material combines CR39’s lightness and polycarbonate’s durability. With a featherweight density (1,11g/cm3), Trivex is the lightest corrective lens material on the market. It also offers very good optical properties, superior to polycarbonate. The Trivex technology corrects some drawbacks traditionally attached to CR39 and polycarbonate. The lens is 20% thinner than CR39 and is shatterproof. Unlike polycarbonate, it is chemical and solvent resistant, making it safe to operate in a variety of work environments. Special new features include a 100% efficient UV filter that absorbs the totality of UVA and UVB for even better eye protection. And to ensure long-lasting aesthetics, the lens doesn’t turn yellow over time.
Why go to Bollé Safety to switch to Trivex?
Trivex properties are so high-performing that its technology was initially used for military purposes. With half of the global population over 20 years old suffering from vision problems, companies have a crucial interest in providing their workers with safety prescription eyewear that ensures optimal protection. Poor vision can lead to massive productivity losses and classic safety eyewear is not a one-size-fits-all product. Did you know that 90% of eye injuries could be prevented with proper protection and care? Wearing adapted and fitted eyewear can be a game-changer for professionals. Bollé Safety offers several ranges of products for plano and prescription lenses, so everyone can have perfect vision and safe working conditions. Bollé Safety’s latest frames, “KLASSEE” and “KURT”, make the most out of the Trivex technology. Thanks to Bollé’s unique global expertise, the KLASSEE model combines bio-sourced materials with side protections on the top and on the bottom of the frames. KURT is a great option with adjustable reinforced arms and an athletic frame for even more protection. The translucent front has been smoked to optimize side vision without being blinded. Lightweight and flexible, Bollé Safety glasses ensure a comfortable and secure experience and diminish risks in the work environment.
For more information, visit https://bit.ly/3e0A43j
About Bollé Safety.
Bollé Safety, the global brand for eye protection. Over our 130 years of existence, we have created more than 500 models of safety glasses. With a wide range of innovative, comfortable, and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release
New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom